Faruk Tas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/724769/publications.pdf

Version: 2024-02-01

174 papers 2,612 citations

257450 24 h-index 42 g-index

175 all docs

175 docs citations

175 times ranked

4477 citing authors

#	Article	IF	Citations
1	Metastatic Behavior in Melanoma: Timing, Pattern, Survival, and Influencing Factors. Journal of Oncology, 2012, 2012, 1-9.	1.3	227
2	Oxidative Stress in Breast Cancer. Medical Oncology, 2005, 22, 011-016.	2.5	102
3	Age is a prognostic factor affecting survival in lung cancer patients. Oncology Letters, 2013, 6, 1507-1513.	1.8	102
4	Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. International Journal of Clinical Oncology, 2013, 18, 839-846.	2.2	94
5	Anemia in Oncology Practice. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 371-379.	1.3	88
6	Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Research, 2006, 16 , 405-411.	1.2	73
7	Clinical and prognostic significance of coagulation assays in lung cancer. Respiratory Medicine, 2013, 107, 451-457.	2.9	71
8	The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients. Acta Oncol \tilde{A}^3 gica, 2005, 44, 161-167.	1.8	67
9	Serum Levels of Leptin and Proinflammatory Cytokines in Advanced-Stage Non-Small Cell Lung Cancer. Medical Oncology, 2005, 22, 353-358.	2.5	65
10	Serum Vascular Endothelial Growth Factor (VEGF) and Interleukin-8 (IL-8) Levels in Small Cell Lung Cancer. Cancer Investigation, 2006, 24, 492-496.	1.3	54
11	Clinical and Prognostic Significance of Coagulation Assays in Gastric Cancer. Journal of Gastrointestinal Cancer, 2013, 44, 285-292.	1.3	54
12	Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival. Molecular and Clinical Oncology, 2013, 1, 788-792.	1.0	48
13	Noncutaneous Melanoma Have Distinct Features from Each Other and Cutaneous Melanoma. Oncology, 2011, 81, 353-358.	1.9	46
14	Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Medical Oncology, 2008, 25, 431-436.	2.5	43
15	Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Cancer Chemotherapy and Pharmacology, 2014, 73, 1163-1171.	2.3	42
16	Factors Influencing the Distribution of Metastases and Survival in Extensive Disease Small Cell Lung Cancer. Acta Oncológica, 1999, 38, 1011-1015.	1.8	40
17	Serum Vascular Endothelial Growth Factor (VEGF) and Bcl-2 Levels in Advanced Stage Non-Small Cell Lung Cancer. Cancer Investigation, 2006, 24, 576-580.	1.3	36
18	Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors. Melanoma Research, 2017, 27, 134-139.	1.2	36

#	Article	IF	CITATIONS
19	The Value of Serum Levels of IL-6, TNF-alpha, and Erythropoietin in Metastatic Malignant Melanoma: Serum IL-6 Level Is a Valuable Prognostic Factor at Least as Serum LDH in Advanced Melanoma. Medical Oncology, 2005, 22, 241-246.	2.5	35
20	An analysis of the most-cited research papers on oncology: which journals have they been published in?. Tumor Biology, 2014, 35, 4645-4649.	1.8	33
21	Tumor Infiltrating Lymphocytes (TILs) May be Only an Independent Predictor of Nodal Involvement but not for Recurrence and Survival in Cutaneous Melanoma Patients. Cancer Investigation, 2017, 35, 501-505.	1.3	31
22	Clinical significance of serum interleukin-18 (IL-18) levels in patients with gastric cancer. Biomedicine and Pharmacotherapy, 2015, 70, 19-23.	5.6	29
23	Clinical and Prognostic Significance of Coagulation Assays in Advanced Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2013, 23, 276-281.	2.5	28
24	Serum bcl-2 and survivin levels in melanoma. Melanoma Research, 2004, 14, 543-546.	1.2	26
25	Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer. Cancer Chemotherapy and Pharmacology, 2008, 61, 721-725.	2.3	26
26	Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases. Medical Oncology, 2008, 25, 346-349.	2.5	23
27	D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients. Cancer Biomarkers, 2015, 15, 405-411.	1.7	23
28	Presence of histological regression as a prognostic factor in cutaneous melanoma patients. Melanoma Research, 2016, 26, 492-496.	1,2	23
29	A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma., 1998, 83, 2475-2480.		22
30	Circulating annexin A2 as a biomarker in gastric cancer patients: Correlation with clinical variables. Biomedicine and Pharmacotherapy, 2015, 69, 237-241.	5.6	22
31	The contribution of countries and world regions in productivity of oncological publication. Annals of Oncology, 2008, 19, 1962-1968.	1.2	21
32	Serum transforming growth factor-beta 1 (TGF- \hat{l}^2 1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma. Tumor Biology, 2014, 35, 7233-7237.	1.8	21
33	Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer. Biomedical Reports, 2016, 4, 609-614.	2.0	21
34	Scalp melanoma is associated with high mitotic rate and is a poor prognostic factor for recurrence and outcome. Melanoma Research, 2017, 27, 387-390.	1,2	21
35	Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer. Tumor Biology, 2014, 35, 3095-3102.	1.8	20
36	Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma. BBA Clinical, 2016, 6, 138-142.	4.1	20

#	Article	IF	CITATIONS
37	Prognostic Role of nm23 Gene Expression in Patients With Ovarian Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 164-167.	1.3	19
38	Coagulation tests show significant differences in patients with breast cancer. Tumor Biology, 2014, 35, 5985-5992.	1.8	19
39	Malignant Melanoma in Turkey: A Single Institution's Experience on 475 Cases. Japanese Journal of Clinical Oncology, 2006, 36, 794-799.	1.3	18
40	Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma. ISRN Dermatology, 2013, 2013, 1-5.	1.9	18
41	Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer. Tumor Biology, 2014, 35, 3125-3132.	1.8	18
42	PLASMA HOMOCYSTEINE, FOLATE AND VITAMIN B12 LEVELS IN PATIENTS WITH LUNG CANCER. Experimental Oncology, 2015, 37, 218-222.	0.1	17
43	Clinical Value of Protein S100 and Melanoma-Inhibitory Activity (MIA) in Malignant Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 225-228.	1.3	16
44	Clinical and prognostic significance of coagulation assays in melanoma. Melanoma Research, 2012, 22, 368-375.	1.2	16
45	The major stressful life events and cancer: stress history and cancer. Medical Oncology, 2012, 29, 1371-1377.	2.5	16
46	Clinical Significance of Circulating Serum Cellular Heat Shock Protein 90 (HSP90) Level in Patients with Cutaneous Malignant Melanoma. Asian Pacific Journal of Cancer Prevention, 2017, 18, 599-601.	1.2	16
47	Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients. Tumor Biology, 2014, 35, 3327-3331.	1.8	15
48	Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer. Tumor Biology, 2014, 35, 9303-9309.	1.8	15
49	Acral Lentiginous Melanoma Is Associated with Certain Poor Prognostic Histopathological Factors but May Not be Correlated with Nodal Involvement, Recurrence, and a Worse Survival. Pathobiology, 2018, 85, 227-231.	3.8	15
50	Serum nectin-2 and nectin-4 are diagnostic in lung cancer: which is superior?. Wiener Klinische Wochenschrift, 2019, 131, 419-426.	1.9	15
51	Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer. Investigational New Drugs, 2008, 26, 363-368.	2.6	14
52	Oral etoposide as first-line therapy in the treatment of patients with advanced classic Kaposi's sarcoma (CKS): a single-arm trial (oral etoposide in CKS). Journal of the European Academy of Dermatology and Venereology, 2013, 27, 789-792.	2.4	14
53	Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer. Tumor Biology, 2015, 36, 2097-2103.	1.8	14
54	Elevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma. Molecular and Clinical Oncology, 2017, 7, 1142-1146.	1.0	14

#	Article	IF	CITATIONS
55	BRAF V600E mutation as a prognostic factor in cutaneous melanoma patients. Dermatologic Therapy, 2020, 33, e13270.	1.7	14
56	Celsite� port and catheter as an intraperitoneal access device in the treatment of ovarian cancer. Journal of Surgical Oncology, 2000, 74, 223-226.	1.7	13
57	Serum Matrix Metalloproteinase-3 and Tissue Inhibitor of Metalloproteinase-1 in Patients with Malignant Melanoma. Medical Oncology, 2005, 22, 039-044.	2.5	13
58	Cardiac involvement in melanoma: A case report and review of the literature. Journal of Cancer Research and Therapeutics, 2010, 6, 359.	0.9	13
59	Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial. Melanoma Research, 2005, 15, 543-548.	1.2	12
60	Clinical significance of serum transforming growth factor-beta 1 (TGF- \hat{l}^21) levels in patients with epithelial ovarian cancer. Tumor Biology, 2014, 35, 3611-3616.	1.8	12
61	Clinical significance of serum epidermal growth factor receptor (EGFR) levels in patients with breast cancer. Cytokine, 2015, 71, 66-70.	3.2	12
62	Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma. Journal of Infection and Chemotherapy, 2017, 23, 196-200.	1.7	12
63	Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival. Molecular and Clinical Oncology, 2017, 7, 1083-1088.	1.0	12
64	Relapse patterns in patients with local and regional cutaneous melanoma. Clinical and Translational Oncology, 2019, 21, 412-419.	2.4	12
65	The Behavior of Turkish Cancer Patients in Fasting During the Holy Month of Ramadan. Japanese Journal of Clinical Oncology, 2014, 44, 705-710.	1.3	11
66	Significant Neutrophilic Emperipolesis in Squamous Cell Carcinoma. Case Reports in Oncological Medicine, 2018, 2018, 1-5.	0.3	11
67	A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5â€fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Cancer, 1998, 83, 2475-2480.	4.1	11
68	Plasma homocysteine, folate and vitamin B12 levels in patients with lung cancer. Experimental Oncology, 2015, 37, 218-22.	0.1	11
69	Temozolomide in combination with fotemustine in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology, 2008, 62, 293-298.	2.3	10
70	A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer. International Journal of Clinical Oncology, 2008, 13, 156-160.	2.2	10
71	Matrix metalloproteinase-9 decreased after chemotherapy in patients with non-small cell lung cancer. Tumori, 2011, 97, 286-289.	1.1	10
72	Age-specific incidence ratios of breast cancer (BC) in Turkey: BC in older people is increasing. Archives of Gerontology and Geriatrics, 2012, 55, 112-115.	3.0	10

#	Article	IF	Citations
73	Exacerbation of psoriasis induced by interferon-alpha treatment for melanoma. Cutaneous and Ocular Toxicology, 2016, 35, 83-84.	1.3	10
74	Prognostic and Predictive Role of Angiogenic Markers in Non- Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2019, 20, 733-736.	1.2	10
75	Clinical significance of serum fibronectin and vitronectin levels in melanoma patients. Melanoma Research, 2014, 24, 475-479.	1.2	9
76	Histological lymphovascular invasion is associated with nodal involvement, recurrence, and survival in patients with cutaneous malignant melanoma. International Journal of Dermatology, 2017, 56, 166-170.	1.0	9
77	Primary tumour ulceration in cutaneous melanoma: its role on TNM stages Japanese Journal of Clinical Oncology, 2021, 51, 192-198.	1.3	9
78	Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. Journal of Experimental and Clinical Cancer Research, 2000, 19, 477-81.	0.4	9
79	Age-specific incidence ratios of lung cancer (LC) in Turkey: LC in older people is increasing. Archives of Gerontology and Geriatrics, 2012, 55, 276-278.	3.0	8
80	Clinical Significance of Coagulation Assays in Metastatic Pancreatic Adenocarcinoma. Journal of Gastrointestinal Cancer, 2013, 44, 404-409.	1.3	8
81	Clinical significance of serum epithelial cell adhesion molecule (EPCAM) levels in patients with lung cancer. Molecular and Cellular Biochemistry, 2014, 396, 307-312.	3.1	8
82	Clinical significance of serum M30 and M65 levels in patients with breast cancer. Biomedicine and Pharmacotherapy, 2014, 68, 1135-1140.	5.6	8
83	Serum levels of vascular cell adhesion molecule-1 (VCAM-1) may have diagnostic, predictive, and prognostic roles in patients with lung cancer treated with platinum-based chemotherapy. Tumor Biology, 2014, 35, 7871-7875.	1.8	8
84	Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome. Molecular and Clinical Oncology, 2016, 4, 655-659.	1.0	8
85	Clinical Significance of Serum Galectin-3 Levels in Gastric Cancer Patients. Journal of Gastrointestinal Cancer, 2016, 47, 182-186.	1.3	8
86	Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 127-131.	2.3	8
87	Clinical significance of serum leptin level in patients with gastric cancer. European Cytokine Network, 2018, 29, 52-58.	2.0	8
88	Combination Chemotherapy with Docetaxel and Irinotecan in Metastatic Malignant Melanoma. Clinical Oncology, 2003, 15, 132-135.	1.4	7
89	Second-Line Docetaxel and Gemcitabine Combination Chemotherapy in Patients with Non-Small-Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy: A Phase II Trial. Medical Oncology, 2004, 21, 233-240.	2.5	7
90	The Value of Serum Bcl-2 Levels in Advanced Lung Cancer Patients. Medical Oncology, 2005, 22, 139-144.	2.5	7

#	Article	IF	CITATIONS
91	Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma. Tumor Biology, 2013, 34, 3529-3536.	1.8	7
92	Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 631-637.	2.3	7
93	Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies. American Journal of Therapeutics, 2016, 23, e670-e679.	0.9	7
94	De Novo and Nevus-Associated Melanomas: Different Histopathologic Characteristics but Similar Survival Rates. Pathology and Oncology Research, 2020, 26, 2483-2487.	1.9	7
95	Assessment of Anxiety and Depression Status in Turkish Cutaneous Melanoma Patients. Asian Pacific Journal of Cancer Prevention, 2017, 18, 369-373.	1.2	7
96	The Value of Serum bcl-2 Levels in Advanced Epithelial Ovarian Cancer. Medical Oncology, 2006, 23, 213-218.	2.5	6
97	Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer. International Journal of Clinical Oncology, 2008, 13, 330-334.	2.2	6
98	Plantar melanoma is associated with certain poor prognostic histopathological factors, but not correlated with nodal involvement, recurrence, and worse survival. Clinical and Translational Oncology, 2018, 20, 607-612.	2.4	6
99	Early and late relapses of cutaneous melanoma patients. Postgraduate Medicine, 2019, 131, 207-211.	2.0	6
100	Limb melanomas: acral melanomas have worse survival. Journal of Dermatological Treatment, 2022, 33, 1630-1637.	2.2	6
101	Different mitotic rates are associated with different prognostic factors, relapses, and survival rates in melanoma. International Journal of Dermatology, 2022, 61, 472-479.	1.0	6
102	MASSIVE AND ISOLATED METASTASES TO SPLEEN OF UVEAL MALIGNANT MELANOMA. Retina, 2004, 24, 170-172.	1.7	5
103	Pattern and Outcome of admission to a medical oncology inpatient service. Journal of Cancer Education, 2007, 22, 80-85.	1.3	5
104	Clinical significance of serum caveolin-1 levels in melanoma patients. International Journal of Dermatology, 2016, 55, 558-562.	1.0	5
105	Clinical significance of serum claudin-1 levels in melanoma patients. Melanoma Research, 2016, 26, 377-381.	1.2	5
106	Effect of biology on the outcome of female melanoma patients. Molecular and Clinical Oncology, 2017, 7, 1093-1100.	1.0	5
107	Anemia in Cutaneous Malignant Melanoma: Low Blood Hemoglobin Level is Associated with Nodal Involvement, Metastatic Disease, and Worse Survival. Nutrition and Cancer, 2018, 70, 236-240.	2.0	5
108	Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer. Biomolecules, 2018, 8, 169.	4.0	5

#	Article	IF	CITATIONS
109	Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients. Neoplasma, 2019, 66, 631-636.	1.6	5
110	Distichiasis in association with entropion in metastatic HER2â€positive breast cancer treated by pertuzumab, trastuzumab, and docetaxel combination chemotherapy. Breast Journal, 2020, 26, 1004-1006.	1.0	5
111	Coexistence of regression and tumor infiltrating lymphocytes is associated with more favorable survival in melanoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2721-2729.	2.5	5
112	Retrovesical Soft-Tissue Metastasis of Malignant Thymoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 366-368.	1.3	4
113	Melanoma-assocıated hypopıgmentatıon ın assocıatıon wıth locoregıonal relapse of melanoma. Surgery, 2011, 150, 1011-1012.	1.9	4
114	Age-specific incidence ratios of colorectal cancer (CRC) in Turkey: CRC in older people is increasing. Archives of Gerontology and Geriatrics, 2012, 55, 279-282.	3.0	4
115	Clinical significance of serum M30 and M65 levels in melanoma. Melanoma Research, 2013, 23, 390-395.	1.2	4
116	The Role of Surgical Methods in the Treatment of Anorectal Malignant Melanoma (AMM). Acta Chirurgica Belgica, 2013, 113, 429-433.	0.4	4
117	Cheek Cutaneous Melanomas. Annals of Plastic Surgery, 2019, 82, 407-410.	0.9	4
118	Palpebral cutaneous melanomas: a review of 17 cases from a tertiary center. International Journal of Dermatology, 2019, 58, 75-79.	1.0	4
119	Awareness on malignant melanoma and its prevention measures among Turkish cutaneous malignant melanoma patients: A tertiary cancer center experience. Dermatologic Therapy, 2020, 33, e14425.	1.7	4
120	Seasons influence diagnosis and outcome of cutaneous melanoma. Dermatologic Therapy, 2020, 33, e13625.	1.7	4
121	Tongue metastasis of melanoma. Journal of Cancer Research and Therapeutics, 2015, 11, 660.	0.9	4
122	The role of surgical methods in the treatment of anorectal malignant melanoma (AMM). Acta Chirurgica Belgica, 2013, 113, 429-33.	0.4	4
123	Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma. Lung Cancer, 2007, 57, 79-83.	2.0	3
124	Classic Kaposi′s sarcoma with colonic involvement: A rare presentation with successful treatment with oral etoposide. Journal of Cancer Research and Therapeutics, 2012, 8, 112.	0.9	3
125	Clinical significance of serum protease-activated receptor-1 levels in gastric cancer patients. Biomedical Reports, 2016, 4, 489-492.	2.0	3
126	Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma. BBA Clinical, 2016, 5, 166-169.	4.1	3

#	Article	IF	Citations
127	Clinical significance of serum laminin levels in patients with lung cancer. Biomedical Reports, 2016, 4, 485-488.	2.0	3
128	Significance of serum neural precursor cellâ€'expressed developmentally downregulated protein 9 in melanoma. Molecular and Clinical Oncology, 2017, 8, 204-208.	1.0	3
129	Digital clubbing as a first clinical presentation of pulmonary metastases in cutaneous melanoma. Postgraduate Medicine, 2018, 130, 278-279.	2.0	3
130	BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha. Cancer Chemotherapy and Pharmacology, 2019, 84, 521-526.	2.3	3
131	Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma. International Journal of Clinical Oncology, 2019, 24, 721-726.	2.2	3
132	Google searching as an indicator of population's interest in melanoma: A comparative study in Google Trends. Dermatologic Therapy, 2020, 33, e14421.	1.7	3
133	Majority of the most-cited articles on cutaneous malignant melanoma are published in non-dermatology/melanoma specialized journals. Journal of Cancer Research and Therapeutics, 2016, 12, 612.	0.9	3
134	Intermediate Dose Interferon Alpha in Adjuvant Treatment for High-Risk Melanoma: A Single Institution's Experience. Medical Oncology, 2006, 23, 471-478.	2.5	2
135	Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?. Tumor Biology, 2014, 35, 4323-4329.	1.8	2
136	Clinical significance of serum laminin and type-IV collagen levels in cutaneous melanoma patients. Molecular and Clinical Oncology, 2016, 5, 195-200.	1.0	2
137	Widespread finger skin metastases of melanoma. Clinical Case Reports (discontinued), 2018, 6, 448-449.	0.5	2
138	Spitzoid cutaneous melanoma is associated with favorable clinicopathological factors and outcome. Journal of Cosmetic Dermatology, 2019, 18, 1841-1845.	1.6	2
139	Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma. Journal of Oncology Pharmacy Practice, 2021, 27, 40-45.	0.9	2
140	Multiple combinations of melanocytic and vascular endothelial markers enhance the detection rate of lymphovascular invasion in cutaneous melanoma. Journal of Cutaneous Pathology, 2021, 48, 472-478.	1.3	2
141	Mitotic rate in node-positive stage III melanoma: it might be as important a prognostic factor as node number. Japanese Journal of Clinical Oncology, 2021, 51, 873-878.	1.3	2
142	Digit melanomas are associated with poor prognostic factors and unfavorable survivals. Journal of Cosmetic Dermatology, 2022, 21, 2120-2129.	1.6	2
143	Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: Retrospective realâ€life data. Dermatologic Therapy, 2021, 34, e15122.	1.7	2
144	Paradox in melanoma. Melanoma Research, 2020, Publish Ahead of Print, .	1.2	2

#	Article	IF	CITATIONS
145	Patellar metastasis of melanoma. Indian Journal of Medical Research, 2013, 138, 370.	1.0	2
146	Clinical significance of serum caveolin-1 levels in gastric cancer patients. Experimental Oncology, 2018, 40, 323-327.	0.1	2
147	Apoptosis of Lymphocytes in Peripheral Blood of Patients with Melanoma. Medical Oncology, 2005, 22, 177-182.	2.5	1
148	Factors Influencing the Hormone Receptor and HER2 Levels in Breast Cancer: A Population-Based Analysis. Onkologie, 2012, 35, 95-98.	0.8	1
149	Is it solitary plasmacytoma or nonsecretory myeloma? A must-be-solved dilemma?. Biomedicine and Pharmacotherapy, 2016, 77, 27-29.	5.6	1
150	The course of stage III melanoma in accordance with the severity of node involvement. Current Medical Research and Opinion, 2019, 35, 1819-1824.	1.9	1
151	Number of Excised Lymph Nodes Has No Impact on Relapse and Survival in Patients With Stage III Melanoma. Annals of Plastic Surgery, 2019, 83, 455-458.	0.9	1
152	Trends in the characteristics of skin melanoma in accordance with time intervals: A single Turkish tertiary referral center experience. Journal of Cancer Research and Therapeutics, 2021, 17, 1119.	0.9	1
153	Clinical significance of serum transforming growth factor beta 1 (TGFB1) level in breast cancer Journal of Clinical Oncology, 2014, 32, e11526-e11526.	1.6	1
154	Successful Treatment of a 92-Year-Old Classic Kaposi's Sarcoma Man With Ultra-Low Dose Oral Etoposide. Journal of Oncology Pharmacy Practice, 2022, , 107815522210782.	0.9	1
155	Tumor Spreading Along an Incisional Scar Line. International Journal of Surgical Pathology, 2006, 14, 143-143.	0.8	0
156	Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer. Oncology Letters, 2013, 5, 1699-1703.	1.8	0
157	Recurrent Gastric Cancer Presenting with Both Scrotal and Facial Skin Metastases: A Case Report. Journal of Gastrointestinal Cancer, 2014, 45, 96-99.	1.3	0
158	Cutaneous melanoma in vicenarians: Patients in their twenties and older patients show similar clinical behaviors and survival rates. Journal of Cosmetic Dermatology, 2020, 19, 2692-2696.	1.6	0
159	Serum 25-Hydroxyvitamin D Level Is Not Associated with Duration and Activity of Disease in Melanoma Patients. Nutrition and Cancer, 2021, 73, 1126-1129.	2.0	0
160	Serum folate and vitamin B12 levels in cutaneous melanoma. Journal of Cosmetic Dermatology, 2021, 20, 3007-3010.	1.6	0
161	Complementary and alternative medicine (CAM) in Turkish cutaneous melanoma patients: A prospective study from tertiary cancer center. Journal of Oncology Pharmacy Practice, 2022, 28, 282-286.	0.9	0
162	Auricular and periauricular melanomas have similar clinicopathologic factors and survival rates. Journal of Cosmetic Dermatology, 2021, , .	1.6	0

#	Article	IF	CITATIONS
163	Unknown Primary Metastatic Melanoma Presented with Extensive Subcutaneous Masses and Lymph Node Enlargements. Indian Journal of Surgery, 0 , 1 .	0.3	0
164	Larger Tumors Are Associated with Poorer Prognostic Factors in Cutaneous Melanoma. Indian Journal of Surgery, 0, , 1.	0.3	0
165	Coagulation assays in breast cancer: Correlation of plasma D-dimer with tumor load and invasiveness in breast cancer patients Journal of Clinical Oncology, 2013, 31, e11592-e11592.	1.6	0
166	Comparison of mucosal and cutaneous melanoma in the head and neck region: Different clinical features and similar outcomes Journal of Clinical Oncology, 2013, 31, e20016-e20016.	1.6	0
167	Clinical significance of serum macrophage migration inhibitory factor (MIF) level in breast cancer Journal of Clinical Oncology, 2014, 32, e11556-e11556.	1.6	0
168	Clinical significance of serum caveolin-1 levels in melanoma Journal of Clinical Oncology, 2014, 32, e20049-e20049.	1.6	0
169	Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in lung cancer Journal of Clinical Oncology, 2014, 32, e22192-e22192.	1.6	0
170	Circulating interleukin-18 (IL-18) as a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma Journal of Clinical Oncology, 2016, 34, e15678-e15678.	1.6	0
171	Diagnostic and prognostic roles of serum interleukin-32 (IL-32) levels in patients with pancreatic adenocarcinoma Journal of Clinical Oncology, 2016, 34, e15680-e15680.	1.6	0
172	Seasons Influence Diagnosis of Breast Cancer in Turkey. Indian Journal of Surgery, 0, , 1.	0.3	0
173	Trunk melanomas: no survival differences between lesion sites. Postgraduate Medicine, 2022, , .	2.0	0
174	Using Google as a Source of Information About Breast Cancer. Indian Journal of Surgery, 0, , .	0.3	0